2-Day Virtual Training (August 10-11, 2023)
(Attend LIVE or Access Recording)
FDA’s GMP Expectations for Phase I and First-in-Man Clinical Trials
Manufacturing an investigational product for the initial pilot clinical trials can be a complex and costly endeavor for developers. These first-in-man and pilot clinical trials, usually conducted with a small number of healthy participants, are primarily aimed at establishing safety. Therefore, they do not require a significant amount of investigational material. Recognizing this, the US FDA allows developers to test early-stage investigational products under relaxed GMP requirements.
During our comprehensive workshop, we will delve into the current regulations, guidance documents, and regulatory strategies that are available for manufacturing an early development stage product for Phase I and first-in-man clinical trials. This training will equip you with valuable insights on how to ensure the quality of the investigational product being tested without the excessive regulatory burden of full-scale GMP manufacturing.
By participating in this training, you will gain a deep understanding of the FDA's GMP expectations for Phase I and First-in-Man Clinical Trials. You will learn practical strategies that will enable you to navigate the regulatory landscape more effectively, ensuring FDA compliance while optimizing your resources.
Why should you attend:
Who will Benefit:
For additional information on the workshop agenda and logistics, please call 410-501-5777 or email: email@example.com